Artículos de revistas
Clinical effects of probiotic or azithromycin as an adjunct to scaling and root planning in the treatment of stage III periodontitis: a pilot randomized controlled clinical trial
Fecha
2021Registro en:
BMC Oral Health (2021) 21:12
10.1186/s12903-020-01276-3
Autor
Morales Chvets, Alicia Alvarovna
Contador Cotroneo, Rafael Ignacio
Bravo, Joel
Carvajal Pavez, Paola Lorena
Silva, Nora
Strauss Avendaño, Franz Josef
Gamonal Aravena, Jorge Antonio
Institución
Resumen
Background: The aim of this triple-blind placebo-controlled parallel-arm randomized clinical trial was to evaluate
the clinical effects of Lactobacillus rhamnosus SP1 or azithromycin as an adjunct to scaling and root planing (SRP) in
patients with stage III periodontitis.
Methods: Forty-seven systemically healthy participants with stage III periodontitis were recruited. Following SRP, the
participants were randomly assigned to one of three treatment modalities; (1) placebo (n = 15), (2) probiotics (n = 16)
and (3) antibiotics-azithromycin (n = 16). The participants were monitored at baseline, 3, 6, 9 and 12 months after
therapy. Probing pocket depth (PPD), bleeding on probing (BOP), clinical attachment loss (CAL) and plaque accumulation
(PI) were evaluated.
Results: All 47 participants completed the study. At 12 months, all groups showed significant improvements of PPD
and PI (p < 0.012) irrespective of the treatment modality and without significant differences between the groups. Probiotics
and azithromycin showed no added benefit in terms of CAL. While the placebo (p = 0.002) and the antibioticazithromycin
(p = 0.002) group showed a significant reduction of BOP, only the placebo group revealed a significant
reduction of CAL at 12 months follow-up (p = 0.003). The number of sites and teeth with PPD ≥ 5, ≥ 6 and ≥ 7 mm
were significantly reduced in all groups at 12 months follow-up (p < 0.025) irrespective of the treatment regime and
without significant differences between the groups.
Conclusion: The use of probiotics or azithromycin as an adjunct to SRP failed to provide additional benefits in the
treatment of stage III periodontitis. The benefits of these two treatment regimes as an adjunct to SRP remain unclear.